# Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression

> **NCT05304663** · PHASE1 · WITHDRAWN · sponsor: **Philogen S.p.A.**

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Onfekafusp alfa
- **DRUG:** Lomustine

## Key facts

- **NCT ID:** NCT05304663
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The Sponsor had no further plan for the study in object
- **Last updated:** 2024-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05304663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05304663, "Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05304663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*